Health and Healthcare
How Bristol-Myers Actually Won by Stopping a Clinical Study
Published:
Last Updated:
Usually when a clinical study is stopped it spells disaster for the company performing the study, but in this case Bristol-Myers Squibb Co. (NYSE: BMY) is bucking that trend and investors are thrilled. Not to mention the reason for stopping this study is not often seen.
The company announced that it has stopped its CheckMate-214 study evaluating Opdivo in combination with Yervoy, considering the study has already hit its primary and secondary endpoints. Based on this interim analysis, an independent Data Monitoring Committee recommended that the trial be stopped early.
The study treating patients with previously untreated advanced or metastatic renal cell carcinoma met its co-primary endpoint, demonstrating superior overall survival (OS) compared to sunitinib in intermediate- and poor-risk patients. The combination also met a secondary endpoint of improved OS versus sunitinib in all randomized patients.
It’s safe to say that this stoppage was a home run, and it will allow for Bristol-Myers to quickly progress with its study.
Vicki Goodman, M.D., head of new asset development, Bristol-Myers Squibb, commented:
This overall survival result from CheckMate -214 highlights the potential of the combination of Opdivo and Yervoy to provide a new treatment option for first-line advanced renal cell carcinoma patients for whom there is a considerable unmet need. The company looks forward to sharing the full results with regulatory authorities and will incorporate these data into the planned European Society for Medical Oncology (ESMO) Congress presentation later this week.
Shares of Bristol-Myers were last seen up about 4% at $62.16, with a consensus analyst price target of $57.86 and a 52-week trading range of $46.01 to $62.42.
24/7 Wall St.Is Your Money Earning the Best Possible Rate? (Sponsor)
Let’s face it: If your money is just sitting in a checking account, you’re losing value every single day. With most checking accounts offering little to no interest, the cash you worked so hard to save is gradually being eroded by inflation.
However, by moving that money into a high-yield savings account, you can put your cash to work, growing steadily with little to no effort on your part. In just a few clicks, you can set up a high-yield savings account and start earning interest immediately.
There are plenty of reputable banks and online platforms that offer competitive rates, and many of them come with zero fees and no minimum balance requirements. Click here to see if you’re earning the best possible rate on your money!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
